Search

Cabergoline

Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. … Cabergoline possesses potent agonist activity on dopamine D2 receptors.

Alectinib

Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. … Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

Pentoxifylline

[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but … its possible use in diverse conditions, including osteoradionecrosis, diabetic kidney disease, and generally any condition associated with fibrosis.

Amaranthus retroflexus pollen

Amaranthus retroflexus pollen is the pollen of the Amaranthus retroflexus plant. Amaranthus retroflexus pollen is mainly used in allergenic testing.

Iopamidol

Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

Selinexor

[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at

Passiflora incarnata flower